Related Experiment Video
Updated: Jul 18, 2025
Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models
Published on: November 11, 2014
Tuning Hsp104 specificity to selectively detoxify α-synuclein.
Korrie L Mack1, Hanna Kim2, Edward M Barbieri3
1Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA; Biochemistry and Molecular Biophysics Graduate Group, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Researchers engineered specific Hsp104 protein variants to target toxic alpha-synuclein aggregates. These variants effectively reduce Parkinson's disease pathology in model organisms, offering a promising therapeutic strategy for neurodegenerative disorders.
Area of Science:
- Biochemistry
- Neuroscience
- Protein aggregation
Background:
- Heat shock protein 104 (Hsp104) is a protein disaggregase that resolves protein aggregates.
- Misfolded proteins like alpha-synuclein, TDP-43, and FUS are implicated in neurodegenerative diseases.
- Existing Hsp104 variants, while potent, lack substrate specificity, leading to off-target effects.
Purpose of the Study:
- To engineer substrate-specific Hsp104 variants to reduce off-target effects.
- To develop Hsp104 variants that selectively target alpha-synuclein toxicity.
Main Methods:
- Altering Hsp104 pore loops to change substrate engagement.
- Testing variant specificity against alpha-synuclein, TDP-43, and FUS toxicity.
- Evaluating efficacy in a C. elegans model of Parkinson's disease.
Main Results:
- Engineered Hsp104 variants selectively suppressed alpha-synuclein toxicity without affecting TDP-43 or FUS.
- Identified variants mitigating alpha-synuclein toxicity through disaggregation or detoxification of soluble conformers.
- Alpha-synuclein-specific variants demonstrated superior reduction of dopaminergic neurodegeneration in vivo compared to non-specific variants.
Conclusions:
- Increasing substrate specificity of Hsp104 variants can mitigate off-target effects.
- Tailored Hsp104 disaggregases show potential as therapeutics for specific neurodegenerative diseases.
- This approach could be broadly applied to develop targeted treatments for protein misfolding disorders.
